Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	201.38	144.53	156.33	126.59	94.51	75.55
Short-Term Investments	90.61	114.71	21.86	12.52	15.18	13.97
Cash & Cash Equivalents	291.99	259.24	178.2	139.11	109.68	89.52
Cash Growth	49.49%	45.48%	28.10%	26.83%	22.53%	-4.08%
Receivables	138.11	114.94	88.8	78.8	66.01	45.38
Inventory	115.49	105.83	103.58	92.81	96.83	110.5
Other Current Assets	9.48	9.58	7.73	7.4	7.16	9.85
Total Current Assets	555.08	489.6	378.32	318.12	279.68	255.24
Property, Plant & Equipment	320.39	315.64	264.57	271.49	280.71	253.55
Long-Term Investments	15.16	15.21	2.41	3.99	0	0
Goodwill and Intangibles	607.06	613.3	37.3	38.87	40.62	41.15
Other Long-Term Assets	76.62	79.16	59.38	39.06	30.23	37.03
Total Long-Term Assets	1,019	1,023	363.67	353.41	351.55	331.73
Total Assets	1,574	1,513	741.99	671.53	631.24	586.97
Accounts Payable	116.7	93.37	84.24	89.55	95.5	77.05
Current Debt	4.37	4.34	6.05	5.18	15.62	10.92
Other Current Liabilities	134.1	127.7	4.57	9.08	1.08	2.04
Total Current Liabilities	255.17	225.41	94.86	103.81	112.2	90.01
Long-Term Debt	622.75	619.3	96.53	99.48	51.65	55.71
Other Long-Term Liabilities	24.05	28.78	21.93	22.72	18.66	13.73
Total Long-Term Liabilities	646.79	648.08	118.47	122.2	70.31	69.43
Total Liabilities	901.96	873.49	213.33	226.01	182.51	159.44
Total Debt	627.12	623.64	102.58	104.66	67.27	66.63
Debt Growth	514.67%	507.94%	-1.99%	55.59%	0.97%	32.68%
Retained Earnings	452.45	409.27	271.72	180.34	117.77	116.37
Comprehensive Income	-8.77	-8.48	-8.62	-6.77	-3.72	-4.69
Shareholders' Equity	672.36	639.42	528.66	445.52	402.31	381.37
Net Cash / Debt	-335.13	-364.4	75.62	34.45	42.41	22.89
Net Cash / Debt Growth	-	-	119.52%	-18.79%	85.29%	-46.90%
Net Cash Per Share	-6.32	-6.88	1.44	0.69	0.86	0.46
Working Capital	299.91	264.19	283.46	214.31	167.48	165.23
Book Value Per Share	13.95	13.25	10.89	9.32	8.55	8.12

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).